Pulmotil 90

RESIDUE WARNING: Swine: Swine intended for human consumption must not be slaughtered within 7 days of the last treatment of this drug product.

RESIDUE WARNING: Cattle: Cattle intended for human consumption must not be slaughtered within 28 days of the last treatment with this drug product.

This drug product is not approved for use in female dairy cattle 20 months of age or older. Use in these cattle may cause drug residues in milk. This drug product is not approved for use in calves intended to be processed for veal. A withdrawal period has not been established in pre-ruminating calves.

User Safety Warnings: Avoid inhalation, oral exposure and direct contact with skin or eyes. Operators mixing and handling Pulmotil 90 should use protective clothing, impervious gloves, goggles and a NIOSH-approved dust mask. Wash thoroughly with soap and water after handling. If accidental eye contact occurs, immediately rinse thoroughly with water. If irritation persists, seek medical attention. Not for human consumption. Keep out of reach of children. The Material Safety Data Sheet contains more detailed occupational safety information. To report adverse effects in users, to obtain more information, or to obtain a Material Safety Data Sheet, call 1-800-428-4441.

Clinical Pharmacology: Oral dosing of tilmicosin phosphate to swine at 181 to 363 g/ton of feed results in serum tilmicosin levels, which do not correlate with efficacy. Lung concentrations of tilmicosin are higher than serum. Following 7 consecutive days of administering tilmicosin-medicated feeds to swine, the concentration of tilmicosin in respiratory tissues, phagocytic cells, and nasal secretions was significantly higher than that of plasma or serum. Lung levels are achieved within 2 days after beginning feeding and plateau by 4 days. Using in-vitro incubation techniques, the ratio of intracellular to extracellular concentrations of tilmicosin for neutrophils, monocyte-macrophages and alveolar macrophages were 69, 19 and 17, respectively, after four hours of incubation. Although lower levels of accumulation were observed in-vivo, swine alveolar macrophages have been shown in-vitro and in-vivo to concentrate large amounts of tilmicosin; these cells may be important for in-vivo distribution of the drug and may serve as an important reservoir for tilmicosin in lung tissue.

Oral dosing of tilmicosin phosphate to cattle to target a dose of 12.5 mg/kg body weight resulted in serum tilmicosin concentrations above the analytical limit of quantification (0.5 ng/mL) within 12 hours following treatment administration. The relationship of serum tilmicosin concentration to lung tilmicosin concentration has not been determined following oral administration of tilmicosin.

Toxicology: The cardiovascular system is the target of toxicity in laboratory and domestic animals given tilmicosin by oral or parenteral routes. Primary cardiac effects are increased heart rate (tachycardia) and decreased contractility (negative inotropy). Given orally, the median lethal dose is 800 mg/kg in fasted rats and 2250 mg/kg in non-fasted rats. No compound-related lesions were found at necropsy. Results of genetic toxicology studies were all negative. Results of teratology and reproduction studies in rats were all negative. The no effect level in dogs after daily oral doses for up to one year is 4 mg/kg of body weight. Tilmicosin was included in the diet of 18 adult horses for a period of 14 days at dose levels of 400, 1200 and 2000 ppm. Some horses at both the low and high dose levels demonstrated gastrointestinal disturbance with more severe colic evident at the higher levels. One horse died after consuming the 2000 ppm diet. A study was conducted in cattle administered oral tilmicosin at 12.5, 25.0 or 37.5 mg/kg for 42 days or administered 12.5 mg/kg of oral tilmicosin for 14 days followed by 20 mg/kg injection of tilmicosin or saline (volume equivalent). Cardiac lesions observed (one animal in the 12.5 mg/kg for 42 days treatment group; one animal in the 12.5 mg/kg for 14 days followed by tilmicosin injection treatment group) were not considered clinically significant as no other abnormalitieswere seen and the affected animals were clinically normal.

To report adverse effects, access medical information or obtain additional product information, call 1-800-428-4441.

Storage Information: Store at less than or equal to 25°C (77°F). Excursions to 40°C (104°F) are acceptable.

Avoid excessive moisture.

Not to be used after the date printed on the bag.

Restricted Drug (California) - Use Only as Directed
NADA # 141-064, Approved by FDA

Manufactured For:
Elanco Animal Health, A Division of Eli Lilly and Company, Indianapolis, IN 46285, USA

Elanco, Pulmotil and the diagonal bar are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

YL086160AMX (V10-07-2012)

Swine: For the control of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae and Pasteurella multocida.

Cattle: For the control of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni in groups of beef and non-lactating dairy cattle, where active BRD has been diagnosed in at least 10% of the animals in the group.